


Figure '



rigure z




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7








Figure 8









■ D269H

■ TRAIL (24/7/02)

Figure 12.

В




Figure 13.




Figure 14






Figure 15












Figure 16

PCT/IB2004/004335










Figure 18

D269H T214R D269H T214R 59.18 37.41 37.53 22.52 21.59 33.27 35.74 Neutralizing aDR4 antibody protects only against TRAIL, not against DR5 specific TRAIL mutants in Colo205 cells Neutralizing aDR4 antibody protects only against TRAIL, not against DR5 specific TRAIL mutants ☐Ligand + aDR4 aDR5/1 □ aDR4 aDR5/1 D269H E195R D269H E195R 23.91 23.69 25.54 25.78 31.33 61.67 CLigand + aDR5/1 23.95 25.2 24.98 24.82 55.63 63.48 27.21 24.47 ⊞ Ligand ■ Ligand + aDR4 17RAIL 60.67 44.25 59.06 38 53.57 44.47 30.29 20.88 ■ no AB Control 10.76 No ligand © Ligand + aDR4
□ Ligand + aDR5/1
□ Ligand + aDR5/1 9 2 8 ß 各 8 8 © no AB ■ aDR4 □ aDR5/1 6 8 S \$ ಜ ន 6 % Cell Death (% Annexin V positivity) % Cell Desth (% Annexin V positivity) Ø œ

Figure 19






Figure 2(








Figure 21